Cohance lifesciences Limited has successfully completed its postal ballot process for a key board appointment, with shareholders overwhelmingly approving the appointment of Mr. Himanshu Agarwal as Whole-time Director. The resolution was passed on January 22, 2026, following a comprehensive remote e-voting process that demonstrated strong shareholder participation and support.

Voting Results and Shareholder Participation

The postal ballot process concluded with decisive shareholder approval, as detailed in the company's regulatory filing to BSE and NSE on January 22, 2026. The voting results showcase broad-based support across different shareholder categories.

Director Appointment Details

The approved resolution pertains to the appointment of Mr. Himanshu Agarwal, bearing Director Identification Number (DIN) 06672915, as a Whole-time Director of the Company. This appointment represents an ordinary resolution that required simple majority approval from shareholders.

E-voting Process and Timeline

The postal ballot was conducted exclusively through remote e-voting in accordance with regulatory requirements. The process was managed by KFin Technologies Limited, serving as the Company's Registrar and Transfer Agent.

Key timeline details include:

• Postal Ballot Notice Date: December 19, 2025
• Notice Distribution: December 23, 2025
• E-voting Commencement: December 24, 2025 at 9:00 AM IST
• E-voting Conclusion: January 22, 2026 at 5:00 PM IST
• Cut-off Date: December 19, 2025

Scrutinizer Report and Compliance

The voting process was overseen by DVM Gopal (ICSI Membership No. F6280), Partner of M/s. DVM & Associates LLP, who served as the appointed Scrutinizer. The scrutinizer's report confirmed that 471 members voted in favor of the resolution representing 33,10,35,115 shares (96.862%), while 51 members voted against representing 1,07,24,106 shares (3.138%). No invalid votes were recorded during the process.

The Company published the mandatory newspaper advertisement in "Business Standard" (English Daily) and "Navshakti" (Marathi Daily) on December 24, 2025, ensuring proper public notification as required under the Companies (Management and Administration) Rules, 2014.

Regulatory Compliance and Documentation

Cohance Lifesciences Limited has made the voting results and scrutinizer's report available on its official website at https://www.cohance.com/shareholder-info-2/ and on KFin Technologies Limited's e-voting platform at https://evoting.kfintech.com/ . The company's filing was signed by Kundan Kumar Jha, Company Secretary, Compliance Officer and Head-Legal, ensuring proper regulatory compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Cohance lifesciences Limited has announced its quarterly earnings conference call to discuss Q3 & 9MFY26 financial results. The pharmaceutical company informed stock exchanges BSE and NSE about the scheduled investor interaction through a regulatory filing dated January 22, 2026.

Conference Call Schedule

The earnings call is scheduled for Thursday, February 12, 2026 at 6:15 PM IST. The session will commence with a brief management discussion on the Q3 & 9MFY26 results, which will be declared earlier on the same day, followed by an interactive Question & Answer session with investors and analysts.

Participation Details

The company has provided comprehensive dial-in information to facilitate participation from domestic and international investors:

Pre-Registration Process

To streamline the connection process, Cohance Lifesciences has enabled pre-registration for participants. Investors can register through the provided link to receive dial-in numbers, passcode, and PIN directly on their registered email addresses. This facility eliminates waiting time for operator assistance during the actual call.

Participants are advised to dial into the conference call 5-10 minutes prior to the scheduled start time to ensure timely connection.

Contact Information

For additional information regarding the conference call, investors can reach out to:

• Cyndrella Carvalho, Head - Investor Relations at Tel: 040 2354 3311, Email: cyndrella.carvalho@cohance.com
• CDR India representatives: Gavin Desa (+91 98206 37649) and Rishab Barar (+91 77770 35061)

The company operates under CIN: L24299MH2018PLC422236 and trades on BSE with scrip code 543064 and NSE with symbol COHANCE. Cohance Lifesciences was formerly known as Suven Pharmaceuticals Limited.